BDX Stock Declines Following Class I Classification for Alaris Recall

Becton, Dickinson and Company’s (BDX) , or popularly known as BD, initiated the recall of its infusion pumps last month after customer reports indicated software issues, potentially leading to inaccurate therapy administration. The FDA designated BD’s recall of its infusion pump software as Class I, the most severe classification, last week. While no injuries or fatalities have been reported, the FDA warns that continued use of the affected software could result in serious harm or even death if appropriate ...